chemo

Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors

July 02, 2025 06:00 ET  | Source: Instil Bio US phase 1 trial of ‘2510 is expected to be initiated before…

2 days ago